(Reuters) -The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to ...

children and adolescents, as well as pregnant and immunocompromised people, where the use of the vaccine outweighs its risks. Children are particularly vulnerable to mpox because their immune ...

The World Health Organisation has given the Bavarian Nordic mpox vaccine the go ahead for use in adolescents aged 12 to 17, an age group which is viewed as especially vulnerable to the disease.

The World Health Organisation on Tuesday approved an mpox vaccine from Japanese pharma company KM Biologics for emergency use, the second one to get the agency's seal of approval. The WHO said it ...

The World Health Organization has given its authorization to a first vaccine to protect ... for children and adolescents younger than 18. More than half of the mpox cases in Congo this year ...

Bavarian Nordic’s Mpox vaccine met with the World Health Organization's approval on Monday for use among adolescents aged between 12-17. This age bracket is considered to be highly vulnerable to ...

The WHO said in a statement that it gave the Jynneos vaccine prequalification for adolescents on Oct. 8. The WHO declared mpox a global public health emergency for the second time in two years in ...

The World Health Organisation (WHO) said on Monday it had approved Bavarian Nordic’s mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks ...